CCK-8-stimulated insulin secretion in vivo is mediated by CCKA receptors

Eur J Pharmacol. 1992 Mar 17;213(1):145-6. doi: 10.1016/0014-2999(92)90245-y.


The effects of the cholecystokinin A (CCKA) receptor antagonist, L-364,718, and the CCKB receptor antagonist, L-365,260, on CCK-8-stimulated insulin secretion were studied in vivo in the mouse. It was found that CCK-8-stimulated insulin secretion was suppressed by L-364,718 at a low dose level (0.078 mumol/kg). In contrast, L-365,260 caused a partial inhibition of CCK-8-stimulated insulin release only at the high dose level (24 mumol/kg). It is concluded that the CCK-8-stimulated insulin release in vivo is mediated by CCK receptors of the CCKA subtype.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Benzodiazepinones / pharmacology*
  • Devazepide
  • Injections, Intravenous
  • Insulin / metabolism*
  • Insulin Secretion
  • Mice
  • Phenylurea Compounds*
  • Receptors, Cholecystokinin / antagonists & inhibitors
  • Receptors, Cholecystokinin / metabolism*
  • Sincalide / pharmacology*


  • Benzodiazepinones
  • Insulin
  • Phenylurea Compounds
  • Receptors, Cholecystokinin
  • L 365260
  • Devazepide
  • Sincalide